Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice

To report the early efficacy and safety outcomes of treatment with intravitreal injections of brolucizumab (IVT-B) in patients presenting neovascular age-related macular degeneration (nAMD) in a tertiary clinical setting. A retrospective case series of patients that received IVT-B with a minimum of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Andrea Montesel, Claudio Bucolo, Ferenc B. Sallo, Chiara M. Eandi
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	brolucizumab anti-vascular endothelial growth factor intravitreal route neovascular age-related macular degeneration retina choroid Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/66aad92b4f694e8eb652eb40ee06dae7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:66aad92b4f694e8eb652eb40ee06dae7
record_format	dspace
spelling	oai:doaj.org-article:66aad92b4f694e8eb652eb40ee06dae72021-11-04T09:00:41ZShort-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice1663-981210.3389/fphar.2021.720345https://doaj.org/article/66aad92b4f694e8eb652eb40ee06dae72021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.720345/fullhttps://doaj.org/toc/1663-9812To report the early efficacy and safety outcomes of treatment with intravitreal injections of brolucizumab (IVT-B) in patients presenting neovascular age-related macular degeneration (nAMD) in a tertiary clinical setting. A retrospective case series of patients that received IVT-B with a minimum of two injections performed and at least 4 weeks of follow-up after last injection. Nineteen eyes of 19 patients were included. The number of IVT-B performed for the whole cohort was 58 injections; the mean number of IVT-B per patient was 3.0 ± 1.0 (range 2–6); the mean follow-up time was 14.4 ± 9.0 weeks. Mean baseline best-corrected visual acuity was 0.4 ± 0.4 logMAR and at the last follow-up was 0.4 ± 0.6 logMAR (p = 0.778). All eyes showed a reduction in retinal thickness, with the central macular thickness being 470 ± 151 μm at baseline and 360 ± 144 μm at the last follow-up (p = 0.001). Intra-retinal fluid was present at baseline in 12 eyes (63%) and in three eyes (16%) at the last follow-up (p = 0.065). Sub-retinal fluid was present at baseline in 17 eyes (89%) and at the last follow-up in three eyes (16%, p = 0.011). Pigment epithelium detachment was apparent in the 16 eyes (84%) at baseline and was still present in 14 eyes (73%, p = 0.811). One adverse event of intraocular inflammation was reported. In conclusion, our short-term experience showed that brolucizumab was highly effective in restoring the anatomy and in stabilizing the visual acuity of eyes with nAMD. Its safety profile should be evaluated carefully and needs further investigations.Andrea MonteselClaudio BucoloFerenc B. SalloChiara M. EandiFrontiers Media S.A.articlebrolucizumabanti-vascular endothelial growth factorintravitreal routeneovascular age-related macular degenerationretinachoroidTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	brolucizumab anti-vascular endothelial growth factor intravitreal route neovascular age-related macular degeneration retina choroid Therapeutics. Pharmacology RM1-950
spellingShingle	brolucizumab anti-vascular endothelial growth factor intravitreal route neovascular age-related macular degeneration retina choroid Therapeutics. Pharmacology RM1-950 Andrea Montesel Claudio Bucolo Ferenc B. Sallo Chiara M. Eandi Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice
description	To report the early efficacy and safety outcomes of treatment with intravitreal injections of brolucizumab (IVT-B) in patients presenting neovascular age-related macular degeneration (nAMD) in a tertiary clinical setting. A retrospective case series of patients that received IVT-B with a minimum of two injections performed and at least 4 weeks of follow-up after last injection. Nineteen eyes of 19 patients were included. The number of IVT-B performed for the whole cohort was 58 injections; the mean number of IVT-B per patient was 3.0 ± 1.0 (range 2–6); the mean follow-up time was 14.4 ± 9.0 weeks. Mean baseline best-corrected visual acuity was 0.4 ± 0.4 logMAR and at the last follow-up was 0.4 ± 0.6 logMAR (p = 0.778). All eyes showed a reduction in retinal thickness, with the central macular thickness being 470 ± 151 μm at baseline and 360 ± 144 μm at the last follow-up (p = 0.001). Intra-retinal fluid was present at baseline in 12 eyes (63%) and in three eyes (16%) at the last follow-up (p = 0.065). Sub-retinal fluid was present at baseline in 17 eyes (89%) and at the last follow-up in three eyes (16%, p = 0.011). Pigment epithelium detachment was apparent in the 16 eyes (84%) at baseline and was still present in 14 eyes (73%, p = 0.811). One adverse event of intraocular inflammation was reported. In conclusion, our short-term experience showed that brolucizumab was highly effective in restoring the anatomy and in stabilizing the visual acuity of eyes with nAMD. Its safety profile should be evaluated carefully and needs further investigations.
format	article
author	Andrea Montesel Claudio Bucolo Ferenc B. Sallo Chiara M. Eandi
author_facet	Andrea Montesel Claudio Bucolo Ferenc B. Sallo Chiara M. Eandi
author_sort	Andrea Montesel
title	Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice
title_short	Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice
title_full	Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice
title_fullStr	Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice
title_full_unstemmed	Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice
title_sort	short-term efficacy and safety outcomes of brolucizumab in the real-life clinical practice
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/66aad92b4f694e8eb652eb40ee06dae7
work_keys_str_mv	AT andreamontesel shorttermefficacyandsafetyoutcomesofbrolucizumabinthereallifeclinicalpractice AT claudiobucolo shorttermefficacyandsafetyoutcomesofbrolucizumabinthereallifeclinicalpractice AT ferencbsallo shorttermefficacyandsafetyoutcomesofbrolucizumabinthereallifeclinicalpractice AT chiarameandi shorttermefficacyandsafetyoutcomesofbrolucizumabinthereallifeclinicalpractice
_version_	1718444964101226496

Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice

Ejemplares similares